



R Morant

Contact

R Morant

Publications (18)

Gramann T, Schmid H, Morant R. Nierenzellkarzinom. Fortschritte in der Systembehandlung. InFo Onkol Hämatol 2017; 5

Strebel R, Winterhalder R, Morant R, Pless M, U H, Fehr M, Gillessen S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 2013; 21:2327-33.

Morant R, Vuaroqueaux V, Diener P, Fürstenberger G, Horica C, Németh T, Sulmoni M, Eppenberger U, Eppenberger-Castori S. Comparison of seminal vesicle, non-malignant and malignant prostate tissues with gene expression patterns using quantitative real-time PCR. Int J Clin Pharmacol Ther 2011; 49:86-7.

Münger-Beyeler C, Bernhard J, Rufibach K, Morant R, Schmid H. Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2008; 16:461-7.

Steinbild S, Burkholder I, Edler L, Hanauske A, Hochhaus A, Strumberg D, Ditttrich C, Gillessen Sommer S, Morant R, Frost A, Mross K, Scheulen M. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. British journal of cancer 2007; 97:1480-5.

Glaus A, Böhme C, Thürlimann B, Ruhstaller T, Hsu Schmitz S, Morant R, Senn H, von Moos R. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006; 17:801-6.

Seium Y, Morant R, Bauer J, Trembleau C, Allal A, Philippe M, Mentha G, Gervaz P, Ruhstaller T, Stupp R, Roth A. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:762-6.

Morant R, Hering F, Hanselmann S, Gschwend A, Wernli M, Cerny T, Rochlitz C, Bauer J, Borner M, Bonomo M, Gillessen Sommer S, Dietrich D, Bernhard J, Schmid H. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. British journal of cancer 2004; 90:1312-7.

Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann B, Bernhard J, Hsu Schmitz S, Schmid H. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32.

D'Addario G, Morant R, Boehme C, Cerny T. Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors. Onkologie 2002; 25:152-7.

Morant R, Hürny C, Hanselmann S, Zulian G, Bauer J, Trinkler F, Jacky E, Thürlimann B, Fey M, Borner M, Maibach R, Bernhard J, Hering F. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:183-8.

Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 1999; 17:1672-9.

Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). *European journal of cancer (Oxford, England : 1990)* 1999; 35:913-20.

Thürlimann B, Castiglione M, Hsu-Schmitz S, Cavalli F, Bonnefoi H, Fey M, Morant R, Löhnert T, Goldhirsch A. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). *European journal of cancer (Oxford, England : 1990)* 1997; 33:1017-24.

Brändle M, Galeazzi R, Morant R, Oesterle M. [Osteopenia in beta-thalassemia major]. *Schweizerische medizinische Wochenschrift* 1996; 126:1867-74.

Binek J, Morant R, Weber A, Schmid U, Hammer B. [MALT-type low-grade B-cell lymphomas of the stomach and *Helicobacter pylori*]. *Schweizerische medizinische Wochenschrift* 1996; 126:841-4.

Thürlimann B, Morant R, Jungi W, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. *Support Care Cancer* 1994; 2:61-5.

Morant R, Thürlimann B, Jungi W, Schmid L, Holdener E, Schmid U, Senn H. [Peripheral spontaneous remission of hairy cell leukemia following transfusion-associated hepatitis C]. *Schweiz Med Wochenschr* 1991; 121:344-6.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch